CClinicalTrials.gg
RecruitingNCT07712354Updated Jul 31, 2026

High-Frequency Electroacupuncture at Cervical Huatuo Jiaji Points Combined With Electromagnetic Field Therapy for Cervical Spondylotic Radiculopathy

An interventional study of High-Frequency Electroacupuncture at Cervical Huatuo Jiaji (EX-B2) and Pulsed Electromagnetic Field Therapy in Cervical Spondylosis, Neck Pain and Cervical Spondylotic Radiculopathy, sponsored by University of Medicine and Pharmacy at Ho Chi Minh City. Recruiting at 1 site in Vietnam. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by University of Medicine and Pharmacy at Ho Chi Minh City · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

Cervical spondylotic radiculopathy (CSR) is one of the most common manifestations of cervical spondylosis and is characterized by neck pain radiating to the upper extremities, sensory disturbances, restricted cervical range of motion, and functional disability. Conservative treatment is recommended as the first-line management for most patients, and electroacupuncture is widely used in Traditional Medicine to relieve pain and improve function.

Cervical Huatuo Jiaji (EX-B2) acupuncture points are anatomically located adjacent to the cervical spinal nerve roots and may provide more targeted therapeutic effects than conventional meridian acupuncture points. Pulsed electromagnetic field (PEMF) therapy has also been used as an adjunctive physical modality to reduce pain and facilitate functional recovery.

This randomized controlled trial aims to evaluate whether high-frequency electroacupuncture at cervical Huatuo Jiaji (EX-B2) points combined with PEMF therapy provides greater improvement in pain intensity, cervical function, and safety outcomes than conventional high-frequency electroacupuncture combined with PEMF therapy in patients with cervical spondylotic radiculopathy caused by cervical spondylosis.

The primary outcome is pain intensity measured using the Visual Analog Scale (VAS). Secondary outcomes include cervical range of motion, Neck Disability Index (NDI), and treatment-related adverse events. Clinical outcomes will be assessed at baseline, after one week of treatment, and at the end of the two-week treatment period.

Read the detailed description

This study is designed as a prospective, randomized, single-blind, parallel-group controlled trial. A total of 104 patients diagnosed with cervical spondylotic radiculopathy caused by cervical spondylosis will be recruited and randomly assigned in a 1:1 ratio into two groups using a computer-generated randomization sequence. Allocation concealment will be ensured using sequentially numbered, opaque, sealed envelopes.

Experimental Group: Patients will receive high-frequency electroacupuncture (100 Hz) at bilateral cervical Huatuo Jiaji (EX-B2) points corresponding to the C4-C5, C5-C6, C6-C7, and C7-T1 spinal segments combined with pulsed electromagnetic field (PEMF) therapy.

Active Comparator Group: Patients will receive high-frequency electroacupuncture (100 Hz) at conventional meridian acupuncture points on the affected side combined with the same pulsed electromagnetic field (PEMF) therapy.

Treatment Procedure:

  • A total of 104 participants will be enrolled, with 52 participants allocated to each study group.
  • Both groups will receive one treatment session daily, Monday through Friday, for two consecutive weeks (10 treatment sessions). Each electroacupuncture session will last approximately 20 minutes.
  • All interventions will be performed according to standardized treatment protocols by licensed Traditional Medicine physicians who have received protocol-specific training before study initiation.
  • No additional acupuncture interventions outside the study protocol will be permitted during the study period.

Data Collection and Evaluation:

Outcome measures will be assessed at three predefined time points:

  • N0: Baseline (before treatment)
  • N7: After one week of treatment
  • N14: End of the two-week treatment period

The primary and secondary outcomes include:

Pain intensity: Measured using the Visual Analog Scale (VAS). Cervical range of motion: Measured using a cervical goniometer. Functional disability: Measured using the Neck Disability Index (NDI). Safety: Recording treatment-related adverse events, including bleeding, hematoma, localized pain, dizziness, needle syncope, allergic reactions, infection, and other intervention-related adverse events throughout the study period.

To ensure objectivity, outcome assessments will be conducted by blinded physicians who are not involved in participant recruitment, treatment administration, or randomization. During data entry and statistical analysis, treatment allocation will be coded as Group A and Group B to minimize assessment bias. Statistical analyses will be performed using Generalized Estimating Equations (GEE), with statistical significance defined as a two-sided P value \<0.05.

02

Conditions studied

  • Cervical Spondylosis
  • Neck Pain
  • Cervical Spondylotic Radiculopathy
03

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Written informed consent to participate in the study.
  • Male or female patients aged 30 years or older.
  • Inpatients or outpatients diagnosed with cervical spondylotic radiculopathy caused by cervical spondylosis at Ho Chi Minh City Hospital of Traditional Medicine.
  • Clinical diagnosis of cervical spondylotic radiculopathy, including:
  • Neck pain radiating to the shoulder and/or upper extremity.
  • Sensory disturbance and/or motor deficit and/or abnormal deep tendon reflexes consistent with the affected cervical nerve root.
  • At least one positive provocative test (Spurling test, cervical percussion/compression test, cervical distraction test, or shoulder abduction relief test).
  • Pain intensity of at least 3 on the Visual Analog Scale (VAS).
  • Clinical evidence of cervical spine syndrome.
  • Cervical spine X-ray demonstrating at least one degenerative finding (osteophytes, intervertebral disc space narrowing, or subchondral sclerosis).

Exclusion criteria

Exclusion Criteria:

  • Cervical radiculopathy caused by conditions other than cervical spondylosis.
  • Cervical myelopathy or other spinal cord disorders requiring surgical intervention.
  • Severe systemic illness, frailty, or medical conditions requiring intensive care, or suspected malignancy indicated by unexplained fever, unexplained weight loss, immunodeficiency, or cancer.
  • Contraindications to acupuncture, including skin infection or ulceration at the acupuncture site, allergy to acupuncture needles, severe needle phobia, or psychiatric disorders preventing cooperation.
  • Current treatment with strong analgesics (including paracetamol/codeine combinations, tramadol, or strong opioids) or other therapies that may interfere with study outcomes.
  • Implanted cardiac pacemakers or other implanted electronic medical devices (e.g., neurostimulators, implantable cardioverter-defibrillators, or insulin pumps).
  • Bleeding disorders or hematologic diseases affecting coagulation.
  • Benign or malignant tumors involving the treatment area or systemic malignancy.
  • Participation in another interventional clinical trial.
  • Inability to communicate effectively in Vietnamese.
  • Pregnant women or women with suspected pregnancy.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    High-Frequency Electroacupuncture at Cervical Huatuo Jiaji (EX-B2) + PEMF

    Participants receive high-frequency electroacupuncture (100 Hz) at bilateral cervical Huatuo Jiaji (EX-B2) points corresponding to the C4-C5, C5-C6, C6-C7, and C7-T1 spinal segments combined with pulsed electromagnetic field (PEMF) therapy. Treatment is administered once daily, Monday through Friday, for two consecutive weeks (10 treatment sessions).

    Procedure: High-Frequency Electroacupuncture at Cervical Huatuo Jiaji (EX-B2) · Device: Pulsed Electromagnetic Field Therapy

  • Active comparator
    Conventional High-Frequency Electroacupuncture (Meridian Points) + PEMF

    Participants receive high-frequency electroacupuncture (100 Hz) at conventional meridian acupuncture points on the affected side combined with the same pulsed electromagnetic field (PEMF) therapy. Treatment is administered once daily, Monday through Friday, for two consecutive weeks (10 treatment sessions).

    Device: Pulsed Electromagnetic Field Therapy · Procedure: Conventional High-Frequency Electroacupuncture

Interventions

  • ProcedureHigh-Frequency Electroacupuncture at Cervical Huatuo Jiaji (EX-B2)

    High-frequency electroacupuncture (100 Hz) is applied to bilateral cervical Huatuo Jiaji (EX-B2) acupuncture points at the C4-C5, C5-C6, C6-C7, and C7-T1 spinal segments using standardized stimulation parameters.

  • DevicePulsed Electromagnetic Field Therapy

    Pulsed electromagnetic field (PEMF) therapy is administered according to the standardized treatment protocol during each treatment session.

  • ProcedureConventional High-Frequency Electroacupuncture

    High-frequency electroacupuncture (100 Hz) is applied to conventional meridian acupuncture points on the affected side according to the standardized treatment protocol.

05

What researchers measure

Primary outcomes

  1. Change in neck pain intensity measured by the Visual Analog Scale (VAS)

    Neck pain intensity will be assessed using a 100-mm Visual Analog Scale (VAS). Participants indicate their pain intensity by marking a point on a horizontal line anchored by "no pain" at 0 mm and "worst imaginable pain" at 100 mm. The score is determined by measuring the distance in millimeters from the "no pain" anchor to the participant's mark, yielding a possible score ranging from 0 to 100 mm. Higher scores indicate greater pain intensity and therefore a worse outcome. Changes from baseline in the VAS score at Day 7 and Day 14 will be compared between the two treatment groups.

    Time frame: Baseline (N0), Day 7 (N7), and Day 14 (N14)

Secondary outcomes

  1. Change in functional disability measured by the Neck Disability Index (NDI)

    Functional disability related to neck pain will be assessed using the 10-item Neck Disability Index (NDI). Each item is scored from 0 to 5, yielding a total score ranging from 0 to 50 points, where 0 indicates no disability and 50 indicates maximum disability. Higher scores indicate greater neck-related disability. Changes from baseline in the total NDI score at Day 7 and Day 14 will be compared between the two treatment groups.

    Time frame: Baseline (N0), Day 7 (N7), and Day 14 (N14)

  2. Change in cervical range of motion (ROM)

    Cervical range of motion (flexion, extension, lateral flexion, and rotation) will be measured using a cervical goniometer. Changes from baseline will be compared between the two treatment groups.

    Time frame: Baseline (N0), Day 7 (N7), and Day 14 (N14)

  3. Treatment-related adverse events

    Treatment-related adverse events, including bleeding, hematoma, localized pain, dizziness, needle syncope, infection, allergic reactions, and other intervention-related adverse events, will be recorded throughout the study.

    Time frame: From the first treatment session until Day 14

06

Study locations

1 of 1 sites recruiting
  • University of Medicine and Pharmacy at Ho Chi Minh City
    Ho Chi Minh City, Vietnam
    Recruiting
07

References and documents

Publications

  • Suzuki A, Daubs MD, Hayashi T, Ruangchainikom M, Xiong C, Phan K, Scott TP, Wang JC. Patterns of Cervical Disc Degeneration: Analysis of Magnetic Resonance Imaging of Over 1000 Symptomatic Subjects. Global Spine J. 2018 May;8(3):254-259. doi: 10.1177/2192568217719436. Epub 2017 Aug 17. PubMed 29796373 ↗
  • Ha Hoang Kiem. Degenerative Joint Diseases: Diagnosis, Treatment and Prevention. Sports and Tourism Publishing House. 2018.
  • Nguyen Thi Uyen Thi, Phan Quan Chi Hieu. Comparison of the analgesic effect between cervical Huatuo Jiaji electroacupuncture and conventional electroacupuncture in patients with cervical spondylotic radiculopathy caused by cervical spondylosis. Master's Thesis. University of Medicine and Pharmacy at Ho Chi Minh City. 2014.
  • Takagi I, Eliyas JK, Stadlan N. Cervical spondylosis: an update on pathophysiology, clinical manifestation, and management strategies. Dis Mon. 2011 Oct;57(10):583-91. doi: 10.1016/j.disamonth.2011.08.024. No abstract available. PubMed 22036114 ↗
  • ICH Harmonised Guideline E6(R3). Guideline for Good Clinical Practice. International Council for Harmonisation. 2025.
  • Li W, Qu Y, Chen S, Zou X, Xia C, Ding D. Research Progress on Acupuncture Treatment for Cervical Spondylotic Radiculopathy. Zhong Yi Xue. 2024;13(10):2672-2677.
  • Guo JK, Cheng K, Zhu XC, Gong LD, Wu JT, Li JY. Clinical Observation on the Electro-acupuncture at Cervical Jiaji Point in the Treatment of Acute Cervical Spondylotic Radiculopathy. Journal of Guangzhou University of Traditional Chinese Medicine. 2023;41(2):373-378. doi:10.13359/j.cnki.gzxbtcm.2024.02.017.
  • Lin JG, Chen WL. Acupuncture analgesia: a review of its mechanisms of actions. Am J Chin Med. 2008;36(4):635-45. doi: 10.1142/S0192415X08006107. PubMed 18711761 ↗
  • Bono CM, Ghiselli G, Gilbert TJ, Kreiner DS, Reitman C, Summers JT, Baisden JL, Easa J, Fernand R, Lamer T, Matz PG, Mazanec DJ, Resnick DK, Shaffer WO, Sharma AK, Timmons RB, Toton JF; North American Spine Society. An evidence-based clinical guideline for the diagnosis and treatment of cervical radiculopathy from degenerative disorders. Spine J. 2011 Jan;11(1):64-72. doi: 10.1016/j.spinee.2010.10.023. PubMed 21168100 ↗
  • Carette S, Fehlings MG. Clinical practice. Cervical radiculopathy. N Engl J Med. 2005 Jul 28;353(4):392-9. doi: 10.1056/NEJMcp043887. No abstract available. PubMed 16049211 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared outside the research team in order to protect participant confidentiality and privacy.

08

Registry details

Key details

Study ID
NCT07712354
Lead sponsor
University of Medicine and Pharmacy at Ho Chi Minh City
Responsible party
Nguyen Dinh Kien (Principal Investigator, University of Medicine and Pharmacy at Ho Chi Minh City) — Principal investigator
First posted
Jul 17, 2026
Start date
Jun 2, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion